ArticleInternational orthopaedics2026
Intraosseous bone marrow concentrate delays total hip arthroplasty in osteoarthritis: A fifteen year matched cohort study with dose-response analysis.
Article in International orthopaedics, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
- Commented on by
Authors and funding
5 authors.
Funding
Abstract
purposeTo evaluate whether intraosseous (IO) autologous bone marrow concentrate (BMC), containing mesenchymal stem cells (MSCs) enumerated in vitro as colony forming unit-fibroblasts (CFU‑F), reduces or delays conversion to total hip arthroplasty (THA) compared with matched conservative care, and to assess the influence of disease progression and CFU‑F dose on outcomes.
methodsA monocentric matched cohort (n = 434 hips; 217 BMC, 217 control) was followed for up to 15 years. Bone marrow was aspirated from the iliac crest, processed into BMC to concentrate nucleated cells, and injected intraosseously into the femoral head under fluoroscopy. Demographics, BMI, osteoarthritis grade, and CFU‑F were recorded. The primary outcome was THA‑free survival by Kaplan-Meier with log‑rank testing. Cox proportional-hazard models provided adjusted effects and predictions.
resultsProgression to THA after 15 years occurred in 16.1% (35 of 217) of patients receiving IO BMC versus 40.1% (87 of 217) of control patients receiving conservative care. Kaplan-Meier curves demonstrate superior THA‑free survival with BMC overall, mild osteoarthritis, and with increased CFU‑F dose. No adverse events were observed. Revision surgeries were not performed in those receiving BMC (0 of 35), compared to an 8.0% revision rate among control patients (7 of 87).
conclusionIO BMC was associated with substantially delayed progression to THA with a CFU‑F dose-response and favourable safety profile. These findings suggest that IO BMC may represent a clinically meaningful joint-preserving option for selected patients with hip osteoarthritis, particularly when performed before advanced disease progression and with higher CFU-F doses.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.